IceCure Medical Ltd., a company specializing in minimally-invasive cryoablation technology for tumor destruction, has filed a prospectus related to its rights offering with the U.S. Securities and Exchange Commission. The offering, which was declared effective on July 9, 2025, allows holders of the company's ordinary shares as of the record date to purchase up to a total of 10,000,000 units. Shareholders were distributed non-transferable subscription rights at no charge. The prospectus provides detailed information about the offering and is available on the SEC's website, while inquiries can be directed to Broadridge Corporate Issuer Solutions, LLC, the appointed Information Agent.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.